New Delhi, Sep 2 (PTI) Alkem Laboratories on Monday said it has inked a patent licensing pact with Takeda Pharmaceutical Company to commercialise Vonoprazan in India.

The medication (in strengths of 10 and 20 mg) is indicated in the treatment of reflux esophagitis (RE) and other indications such as gastric ulcers and duodenal ulcers, among others.

Also Read | Shillong Teer Results Today, September 2 2024: Check Winning Numbers, Result Chart for All Shillong Morning Teer, Shillong Night Teer, Khanapara Teer, Juwai Teer and Jowai Ladrymbai Games.

"The company has a formidable presence in the gastrointestinal segment and this non-exclusive patent licence with Takeda will help us offer a product with novel mechanism of action for a large number of patients in India who are suffering from gastro-related ailments," Alkem Laboratories CEO Vikas Gupta said in a statement.

Shares of the drug firm on Monday ended 1.66 per cent down at Rs 6,065.15 apiece on BSE.

Also Read | Aadhaar Card Update: Last Date To Update Aadhaar for Free Is September 14; Know Online Process To Update UIDAI Card Details.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)